Autonomous AI is finally here - or is it? A recent breakthrough IIb regulatory approval raises questions, and perhaps sets the scene for upcoming legislative changes to how healthcare is practiced.

Hardian supported Ross Parkman, Technical Director at Neuronostics, a company on a mission to improve the lives of people with epilepsy to gain their initial CE mark.

'Personalised medicine' is accelerating in clinical interventions (e.g. in genomics, pharmaceuticals, surgical implants and synthetic organoids). Now it's time to think about 'personalised medicine' in terms of the data we use to make clinical decisions and measure outcomes.

Transparency around AI is the first step to building trust, but we still have some way to go to earning that trust in medical AI.

Your guide to Good Machine Learning Practice within regulatory frameworks

Hardian Health announces partnership with Aidence and the University of Edinburgh to evaluate Veye chest under the NHS AAC Award.

Hardian worked closely with Miguel, co-founder of Spotlab and Adriana, Spotlab’s biomedical engineer and regulatory affairs manager to assist them with CE marking for their software IVD.

Hardian supported Koios Medical to help their CEO Chad and this American team to navigate the minefield that is EU medical device regulation, and gain a footing here in Europe with a Class IIa CE mark.

The UK Regulatory Horizons Council recently published their report on the possibilities of UK medical device regulations after Brexit. Normally, any sane person wouldn’t blink an eye about such a mundane and bureaucratic process - but actually, there’s some serious ramifications.

The US FDA and the EU MDR, while ostensibly serving the same purpose of vetting and clearing novel medical devices, do so in subtly different ways. What got you here, won’t get you there - learn more about converting from one regulatory system to another.

Brexit is here, for better or worse. And that means changes to how international manufacturers of software-based medical devices must register with the MHRA.

Can you patent an algorithm? If you assume the answer is no, you could well be missing out on commercially valuable protection. Find out more…

Find out how the new UKCA regulatory changes will affect medical device companies on a global scale.

For investors looking at a health technology business, their intellectual property position will play a significant role in any decision to invest. Find out more on how to protect your IP and satisfy investors.

The worst person you can fool about your product’s value is yourself. It’s time to take a reality check on the feasibility and risks of your grand idea.

Learn the five key questions you need to ask AI vendors, giving you the low-down on common marketing misunderstandings, statistical obfuscation, and creative stretching of medical device regulation.

For innovative health technology, the only route to market is regulatory approval. The only route to regulatory approval is clinical evidence. You’ll need experts in both.

Health tech has suddenly found its new focus in Coronavirus - but are we at risk of doing more harm than good by rushing to use unproven solutions? To avoid chaos in the aftermath, we should focus on tried-and tested tech, and only use novel solutions where need is deemed greater than the acceptable risk.